Shinpoong Pharmaceutical Co., Ltd. AI Stock Analysis
Want to see KR:019170 full AI Analyst Report?
Shinpoong Pharmaceutical Co., Ltd. (019170) AI Stock Analysis
Shinpoong Pharmaceutical Co., Ltd.
(Korea Exchange:019170)
The score is held up by a relatively solid balance sheet with manageable leverage, but is weighed down by unstable profitability (TTM back to a slight loss with margin pressure) and weakening free cash flow momentum. Technically, the stock is in a clear downtrend (below key moving averages with negative MACD), while valuation is difficult to justify due to a negative P/E and no stated dividend yield.
Shinpoong Pharmaceutical Co., Ltd. (019170) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 409.53B
- Dividend Yield
- ―
- Average Volume (3M)
- 524.13K
- Price to Earnings (P/E)
- -829.3
- Beta (1Y)
- 0.31
- Revenue Growth
- 6.21%
- EPS Growth
- 95.65%
- Country
- KR
- Employees
- 815
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Shinpoong Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Shinpoong Pharmaceutical Co., Ltd. is a South Korean company that manufactures and distributes a broad spectrum of pharmaceutical products. Its portfolio includes both cephalosporin and penicillin antibiotics, alongside other finished medications. Th...
Shinpoong Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Balance sheet strength is a key support (moderate leverage with debt-to-equity ~0.19 TTM). However, profitability remains inconsistent: after returning to profitability in 2025, TTM slipped back to a slight net loss with sharp operating margin compression. Cash flow is improved versus prior loss years but durability is uncertain, with free cash flow down ~33% TTM and weak cash conversion versus earnings.
Income Statement
46NeutralBalance Sheet
74PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 239.07B | 234.68B | 221.09B | 200.23B | 209.29B | 189.24B |
| Gross Profit | 101.27B | 102.37B | 81.80B | 80.28B | 77.97B | 77.39B |
| EBITDA | 14.57B | 25.65B | -27.14M | -39.81B | -21.92B | 3.89B |
| Net Income | -815.28M | 8.83B | -15.39B | -57.33B | -35.31B | -11.53B |
Balance Sheet | ||||||
| Total Assets | 366.50B | 352.47B | 342.09B | 350.08B | 361.54B | 392.58B |
| Cash, Cash Equivalents and Short-Term Investments | 72.30B | 71.50B | 56.46B | 60.46B | 55.92B | 92.70B |
| Total Debt | 53.28B | 55.86B | 54.60B | 46.15B | 1.93B | 1.18B |
| Total Liabilities | 88.47B | 81.74B | 84.00B | 79.30B | 30.78B | 38.03B |
| Stockholders Equity | 277.18B | 269.98B | 256.82B | 269.59B | 329.61B | 353.49B |
Cash Flow | ||||||
| Free Cash Flow | 13.57B | 13.78B | -21.24B | -39.88B | -32.67B | -76.64B |
| Operating Cash Flow | 17.57B | 17.25B | -15.15B | -24.85B | -26.44B | -71.03B |
| Investing Cash Flow | -11.16B | -14.71B | 5.58B | -16.31B | 43.20B | 49.03B |
| Financing Cash Flow | 2.14B | 3.70B | 6.20B | 43.24B | -1.87B | -6.42B |
Shinpoong Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:019170, the sentiment is Negative. The current price of 7920.00 is below the 20-day moving average (MA) of 8428.50, below the 50-day MA of 9168.80, and below the 200-day MA of 9952.55, indicating a bearish trend. The MACD of -325.05 indicates Positive momentum. The RSI at 36.51 is Neutral, neither overbought nor oversold. The STOCH value of 53.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:019170.
Shinpoong Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
KR:00106071Outperform
KR:24942060Neutral
KR:00929052Neutral
KR:01917051Neutral
KR:00300050Neutral
KR:17090046Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | KRW 570.85B | 5.64 | ― | 2.75% | 10.50% | 96.29% | |
| 60Neutral | KRW 397.47B | 22.91 | ― | 1.59% | 2.12% | -41.73% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | KRW 294.94B | 24.73 | ― | 1.59% | 5.20% | -65.65% | |
| 51Neutral | KRW 408.79B | -829.32 | ― | ― | 6.21% | 95.65% | |
| 50Neutral | KRW 393.18B | 68.96 | ― | 3.14% | 22.17% | -38.54% | |
| 46Neutral | KRW 324.63B | -55.69 | ― | 2.06% | 15.38% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:019170 | Shinpoong Pharmaceutical Co., Ltd. | 7920.00 | -6670.00 | -45.72% | |
| KR:001060 | JW Pharmaceutical Corporation | 23650.00 | -876.45 | -3.57% | |
| KR:003000 | Bukwang Pharmaceutical Co., Ltd. | 3985.00 | 211.39 | 5.60% | |
| KR:009290 | Kwang Dong Pharmaceutical Co., Ltd. | 6270.00 | 348.93 | 5.89% | |
| KR:170900 | Dong-A ST Co., Ltd. | 34050.00 | -15589.28 | -31.41% | |
| KR:249420 | Ildong Pharmaceutical Co., Ltd. | 12570.00 | -17877.35 | -58.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026
